查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
GLP-1 類似物的全球市場：按產品、形式、給藥途徑和適應症 - 預測（~2032 年）
市場調查報告書
商品編碼
1516916

GLP-1 類似物的全球市場：按產品、形式、給藥途徑和適應症 - 預測（~2032 年）

GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032
出版日期: | 出版商: MarketsandMarkets | 英文 316 Pages | 訂單完成後即時交付

價格

全球 GLP-1 類似物市場規模預計將從 2024 年的 474 億美元增至 2032 年的 4,711 億美元，預測期內複合年成長率為 33.2%。該市場的主要成長動力包括用於治療慢性肥胖和體重管理的GLP-1藥物類別的日益普及，以及用於治療第2型糖尿病的GLP-1類似物的高效能。此外，專注於開發便捷形式的 GLP-1 藥物（例如口服劑型和單劑量自動注射器）的技術創新預計將推動市場成長。

調查範圍
調查年份 2022-2032
基準年 2023年
預測期 2024-2032
單元 百萬/十億美元
部分 依產品、格式、給藥途徑、適應症和最終用戶
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲

“從產品來看，Zepbound（Tirzepatide）預計將成為市場上成長最快的產品。”

Zepbound 在預測期內將繼續成長，原因包括其作為減肥藥的核准、自 2023 年推出以來收益快速成長，以及用於肥胖和體重管理的Tirzepatide的採用率預計將成長最快。

“以產品形式來看，單劑量形式佔據了最大的市場佔有率。”

2023年，單劑量形式佔據最大市場佔有率。此細分市場的成長可歸因於單劑量形式的給藥便利性和注射次數較少，以及單劑量自動注射器的可得性。

“北美佔據了最大的市場佔有率。”

北美地區的巨大佔有率可歸因於政府機構以及製藥和生物技術公司對生物醫學研究的投資和資助的增加。由於大多數 GLP-1 產品已在該地區上市，新技術和替代療法的早期採用進一步支持了市場成長。此外，該地區多個市場參與企業的強大存在也是支持市場成長的關鍵因素之一。這些主要企業包括禮來公司（美國）、諾和諾德公司（丹麥）等。

“歐洲：第二大市場區域”

歐洲市場是GLP-1類似藥物的第二大市場。這是由於該地區擁有眾多學術和研究機構、市場參與企業和政府機構投資增加以及對研發活動的關注增加。

本報告研究和分析了全球 GLP-1 模擬市場，提供了關鍵促進因素和限制因素、競爭格局和未來趨勢的資訊。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

  • GLP-1 模擬市場概述
  • 北美 GLP-1 類似物市場佔有率，按適應症和國家分類（2023 年）
  • 依產品分類的 GLP-1 模擬市場佔有率(2024/2032)
  • 依適應症分類的 GLP-1 模擬市場佔有率(2023)
  • 按最終用戶分類的 GLP-1 模擬市場佔有率（2024 年和 2032 年）
  • GLP-1 模擬市場：地理成長機會

第5章市場概況

  • 介紹
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 影響客戶業務的趨勢/干擾
  • 價格分析
    • GLP-1類似物平均售價的趨勢
    • 主要 GLP-1 類似物的平均售價：按國家/地區分類
  • 技術分析
    • 主要技術
    • 鄰近技術
  • 管道分析
  • 交易資料
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系分析
    • GLP-1類似物市場：原料供應商的作用
    • GLP-1 模擬市場：產品供應商和第 3 階段研發線產品公司的作用
    • GLP-1 模擬市場：最終使用者角色
    • GLP-1類似物市場：監管機構的作用
  • 波特五力分析
  • 主要相關利益者和採購標準
  • 監管環境
    • 監管場景
    • 監管機構、政府機構和其他組織
  • 重大會議和活動（2024-2025）
  • 案例研究
    • 替TirzepatideGLP-1藥品市場研究
    • Ozempic 的仿單標示外使用
  • 投資金籌措場景

第 6 章 GLP-1 類比市場：依產品

  • 介紹
  • 臭氧
  • 特魯利西蒂
  • 曼札羅
  • 烏哥比
  • 自由人
  • 薩克森達
  • 維克托扎
  • 索爾特菲
  • 索利誇
  • 澤普邦德
  • 比杜里翁
  • 其他產品

第 7 章 GLP-1 類比市場：依格式

  • 介紹
  • 單一劑量
  • 多劑量
  • 錠劑

第 8 章 GLP-1 類比市場：依途徑

  • 介紹
  • 皮下注射
  • 口服給藥

第 9 章 GLP-1 類比市場：依指示

  • 介紹
  • 糖尿病
  • 肥胖
  • 其他適應症

第 10 章 GLP-1 模擬市場：依最終用戶分類

  • 介紹
  • 居家照護環境
  • 長期照護設施
  • 醫院/專科診所

第 11 章 GLP-1 類比市場：按地區

  • 介紹
  • 北美洲
    • 經濟衰退對北美的影響
    • 美國
    • 加拿大
  • 歐洲
    • 經濟衰退對歐洲的影響
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 經濟衰退對亞太地區的影響
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 經濟衰退對拉丁美洲的影響
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東
    • 經濟衰退對中東的影響
    • 海灣合作理事會國家
    • 其他中東地區
  • 非洲

第12章競爭格局

  • 概述
  • 主要企業策略/主要企業
  • 收益分析
  • 市場佔有率分析
  • 企業評價矩陣：主要企業（2023年）
  • 公司評等矩陣：正在開發產品的公司 (2023)
  • 企業評估矩陣：Start-Ups/中小企業（2023）
  • 評價及財務指標
  • 品牌/產品比較
  • 競爭場景

第13章 公司簡介

  • 介紹
  • 主要企業
    • NOVO NORDISK A/S
    • ELI LILLY AND COMPANY
    • SANOFI
    • ASTRAZENECA
    • JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • INNOVENT
    • PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
    • SCIWIND BIOSCIENCES CO., LTD.
    • ZEALAND PHARMA A/S
    • BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
  • 其他公司
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • VTV THERAPEUTICS
    • TERNS PHARMACEUTICALS, INC.
    • ALTIMMUNE
    • SCOHIA PHARMA, INC.
    • STRUCTURE THERAPEUTICS
    • NEUROBO PHARMACEUTICALS, INC.
    • I2O THERAPEUTICS, INC.
    • AMGEN INC.
    • PFIZER INC.
    • MERCK & CO., INC.
    • HANMI PHARM CO., LTD.
    • VIKING THERAPEUTICS
    • JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

第14章附錄

Product Code: PH 9080

The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period. The key factors driving the growth of the GLP-1 Analogues market include the growing popularity of the GLP-1 drug class for the treatment of chronic obesity and weight management and high efficacy of GLP-1 analogues for treating type 2 diabetes. Additionally, innovation focusing on the development of convenient forms of GLP-1 drugs, such as oral dosage forms and single dose autoinjectors, are expected to drive growth of GLP-1 analogues market.

Scope of the Report
Years Considered for the Study2022-2032
Base Year2023
Forecast Period2024-2032
Units ConsideredMillion/Billion (USD)
SegmentsBy Product, Format, Route of Administration, Indication, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.

"By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market"

Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.

"By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market"

Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.

"North America: accounted for the largest share of the GLP-1 Analogues market"

North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).

"Europe: The second-largest region in the GLP-1 Analogues market."

The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
  • By Country: North America- 40%, Europe- 30%, Asia Pacific- 20%, Latin America- 5%, and Middle East and Africa- 5%

Prominent Players

Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)

Research Coverage:

This report provides a detailed picture of the GLP-1 Analogues market. It aims to estimate the size and future growth potential of the market across different segments, such as the product, product format, route of administration, indication, end user, and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the GLP-1 Analogues market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provides insights on the following pointers"

  • Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1 Analogues market.
  • Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.
  • Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 MARKET SIZE ASSESSMENT
  • 2.3 MARKET GROWTH FORECAST
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 LIMITATIONS
  • 2.7 RISK ANALYSIS
  • 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 GLP-1 ANALOGUES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE, BY INDICATION AND COUNTRY (2023)
  • 4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032
  • 4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023
  • 4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032
  • 4.6 GLP-1 ANALOGUES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Strong R&D pipeline
      • 5.2.1.2 Improved relative efficacy of GLP-1 drugs
      • 5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High barriers for new entrants due to duopoly
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Extended therapeutic uses
      • 5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Off-label use of GLP-1 drugs
      • 5.2.4.2 High non-adherence to therapy after 12-24 months
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES
    • 5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION
  • 5.5 TECHNOLOGY ANALYSIS
    • 5.5.1 KEY TECHNOLOGIES
      • 5.5.1.1 Chemical Synthesis
      • 5.5.1.2 Recombinant DNA Technology
    • 5.5.2 ADJACENT TECHNOLOGIES
      • 5.5.2.1 Hydrogel Depot Technology
      • 5.5.2.2 Technologies for oral delivery of GLP-1 analogues
  • 5.6 PIPELINE ANALYSIS
  • 5.7 TRADE DATA
  • 5.8 PATENT ANALYSIS
    • 5.8.1 METHODOLOGY
    • 5.8.2 INNOVATION AND PATENT APPLICATIONS
    • 5.8.3 TOP APPLICANTS
  • 5.9 VALUE CHAIN ANALYSIS
  • 5.1 SUPPLY CHAIN ANALYSIS
  • 5.11 ECOSYSTEM ANALYSIS
    • 5.11.1 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
    • 5.11.2 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
    • 5.11.3 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
    • 5.11.4 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 THREAT OF NEW ENTRANTS
    • 5.12.2 THREAT OF SUBSTITUTES
    • 5.12.3 BARGAINING POWER OF SUPPLIERS
    • 5.12.4 BARGAINING POWER OF BUYERS
    • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES
  • 5.14 REGULATORY LANDSCAPE
    • 5.14.1 REGULATORY SCENARIO
    • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.14.2.1 North America
      • 5.14.2.2 Europe
      • 5.14.2.3 Asia Pacific
      • 5.14.2.4 Rest of the World
  • 5.15 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.16 CASE STUDIES
    • 5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET
    • 5.16.2 OZEMPIC OFF-LABEL USE
  • 5.17 INVESTMENT AND FUNDING SCENARIO

6 GLP-1 ANALOGUES MARKET, BY PRODUCT

  • 6.1 INTRODUCTIONS
  • 6.2 OZEMPIC
    • 6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH
  • 6.3 TRULICITY
    • 6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH
  • 6.4 MOUNJARO
    • 6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN NORTH AMERICA
  • 6.5 WEGOVY
    • 6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH
  • 6.6 RYBELSUS
    • 6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET
  • 6.7 SAXENDA
    • 6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH
  • 6.8 VICTOZA
    • 6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH
  • 6.9 XULTOPHY
    • 6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH
  • 6.1 SOLIQUA
    • 6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH
  • 6.11 ZEPBOUND
    • 6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE
  • 6.12 BYDUREON
    • 6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH
  • 6.13 OTHER PRODUCTS

7 GLP-1 ANALOGUES MARKET, BY FORMAT

  • 7.1 INTRODUCTIONS
  • 7.2 SINGLE DOSE
    • 7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH
  • 7.3 MULTI-DOSE
    • 7.3.1 LOW COST TO ATTRACT LARGER ADOPTION
  • 7.4 TABLETS
    • 7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH

8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1 INTRODUCTION
  • 8.2 SUBCUTANEOUS ADMINISTRATION
    • 8.2.1 PEN INJECTORS
      • 8.2.1.1 Ease of monitoring to support adoption
    • 8.2.2 AUTOINJECTORS
      • 8.2.2.1 Advantages offered over pen injectors to support adoption
  • 8.3 ORAL ADMINISTRATION
    • 8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE

9 GLP-1 ANALOGUES MARKET, BY INDICATION

  • 9.1 INTRODUCTION
  • 9.2 DIABETES
    • 9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH
  • 9.3 OBESITY
    • 9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET
  • 9.4 OTHER INDICATIONS

10 GLP-1 ANALOGUES MARKET, BY END USER

  • 10.1 INTRODUCTIONS
  • 10.2 HOME CARE SETTINGS
    • 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
  • 10.3 LONG-TERM CARE FACILITIES
    • 10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET
  • 10.4 HOSPITALS & SPECIALTY CLINICS
    • 10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH

11 GLP-1 ANALOGUES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • 11.2.2 US
      • 11.2.2.1 Strategic developments by major players and R&D activities to drive market
    • 11.2.3 CANADA
      • 11.2.3.1 Strong research infrastructure and availability of funding to support market growth
  • 11.3 EUROPE
    • 11.3.1 EUROPE: RECESSION IMPACT
    • 11.3.2 GERMANY
      • 11.3.2.1 Improving accessibility to support market growth in Germany
    • 11.3.3 UK
      • 11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth
    • 11.3.4 FRANCE
      • 11.3.4.1 Growing awareness to propel market growth
    • 11.3.5 ITALY
      • 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
    • 11.3.6 SPAIN
      • 11.3.6.1 Favorable initiatives for research to drive market
    • 11.3.7 NETHERLANDS
      • 11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
    • 11.3.8 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 11.4.2 CHINA
      • 11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market
    • 11.4.3 JAPAN
      • 11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market
    • 11.4.4 INDIA
      • 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Access to GLP-1 drugs and government support to drive market
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Collaborations in obesity drugs to propel market growth
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 LATIN AMERICA: RECESSION IMPACT
    • 11.5.2 BRAZIL
      • 11.5.2.1 Brazil to hold largest market share in Latin America
    • 11.5.3 MEXICO
      • 11.5.3.1 Growing diabetes and obesity cases to support market growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    • 11.6.1 MIDDLE EAST: RECESSION IMPACT
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Saudi Arabia
        • 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
      • 11.6.2.2 UAE
        • 11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth
      • 11.6.2.3 Rest of GCC countries
    • 11.6.3 REST OF MIDDLE EAST
  • 11.7 AFRICA
    • 11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
    • 11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET
  • 12.3 REVENUE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
  • 12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
    • 12.6.1 STARS
    • 12.6.2 EMERGING LEADERS
    • 12.6.3 PERVASIVE PLAYERS
    • 12.6.4 PARTICIPANTS
    • 12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.6.5.1 Company Footprint
      • 12.6.5.2 Format footprint
      • 12.6.5.3 Route of administration footprint
      • 12.6.5.4 Indication footprint
      • 12.6.5.5 Region footprint
  • 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.7.1 PROGRESSIVE COMPANIES
    • 12.7.2 RESPONSIVE COMPANIES
    • 12.7.3 DYNAMIC COMPANIES
    • 12.7.4 STARTING BLOCKS
    • 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.8 VALUATION & FINANCIAL METRICS
    • 12.8.1 FINANCIAL METRICS
    • 12.8.2 COMPANY VALUATION
  • 12.9 BRAND/PRODUCT COMPARISON
  • 12.1 COMPETITIVE SCENARIO
    • 12.10.1 PRODUCT APPROVALS
    • 12.10.2 DEALS
    • 12.10.3 EXPANSIONS
    • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYERS
    • 13.2.1 NOVO NORDISK A/S
      • 13.2.1.1 Business overview
      • 13.2.1.2 Products offered
      • 13.2.1.3 Recent developments
        • 13.2.1.3.1 Product approvals
        • 13.2.1.3.2 Expansions
        • 13.2.1.3.3 Other developments
      • 13.2.1.4 MnM view
        • 13.2.1.4.1 Right to win
        • 13.2.1.4.2 Strategic choices
        • 13.2.1.4.3 Weaknesses & competitive threats
    • 13.2.2 ELI LILLY AND COMPANY
      • 13.2.2.1 Business overview
      • 13.2.2.2 Products offered
      • 13.2.2.3 Recent developments
        • 13.2.2.3.1 Product approvals
        • 13.2.2.3.2 Deals
        • 13.2.2.3.3 Expansions
      • 13.2.2.4 MnM view
        • 13.2.2.4.1 Right to win
        • 13.2.2.4.2 Strategic choices
        • 13.2.2.4.3 Weaknesses & competitive threats
    • 13.2.3 SANOFI
      • 13.2.3.1 Business overview
      • 13.2.3.2 Products offered
      • 13.2.3.3 MnM view
        • 13.2.3.3.1 Key strengths
        • 13.2.3.3.2 Strategic choices
        • 13.2.3.3.3 Weaknesses & competitive threats
    • 13.2.4 ASTRAZENECA
      • 13.2.4.1 Business overview
      • 13.2.4.2 Products offered
      • 13.2.4.3 Recent developments
        • 13.2.4.3.1 Product approvals
      • 13.2.4.4 MnM view
        • 13.2.4.4.1 Right to win
        • 13.2.4.4.2 Strategic choices
        • 13.2.4.4.3 Weaknesses & competitive threats
    • 13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
      • 13.2.5.1 Business overview
      • 13.2.5.2 Products offered
    • 13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 13.2.6.1 Business overview
      • 13.2.6.2 Products in pipeline
      • 13.2.6.3 Recent developments
        • 13.2.6.3.1 Deals
        • 13.2.6.3.2 Other developments
    • 13.2.7 INNOVENT
      • 13.2.7.1 Business overview
      • 13.2.7.2 Products in pipeline
      • 13.2.7.3 Recent developments
        • 13.2.7.3.1 Other developments
    • 13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
      • 13.2.8.1 Business overview
      • 13.2.8.2 Products in pipeline
    • 13.2.9 SCIWIND BIOSCIENCES CO., LTD.
      • 13.2.9.1 Business overview
      • 13.2.9.2 Products in pipeline
      • 13.2.9.3 Recent developments
        • 13.2.9.3.1 Deals
        • 13.2.9.3.2 Other developments
    • 13.2.10 ZEALAND PHARMA A/S
      • 13.2.10.1 Business overview
      • 13.2.10.2 Products in pipeline
      • 13.2.10.3 Recent developments
        • 13.2.10.3.1 Deals
        • 13.2.10.3.2 Other developments
    • 13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
      • 13.2.11.1 Business overview
      • 13.2.11.2 Products in pipeline
  • 13.3 OTHER PLAYERS
    • 13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 13.3.2 VTV THERAPEUTICS
    • 13.3.3 TERNS PHARMACEUTICALS, INC.
    • 13.3.4 ALTIMMUNE
    • 13.3.5 SCOHIA PHARMA, INC.
    • 13.3.6 STRUCTURE THERAPEUTICS
    • 13.3.7 NEUROBO PHARMACEUTICALS, INC.
    • 13.3.8 I2O THERAPEUTICS, INC.
    • 13.3.9 AMGEN INC.
    • 13.3.10 PFIZER INC.
    • 13.3.11 MERCK & CO., INC.
    • 13.3.12 HANMI PHARM CO., LTD.
    • 13.3.13 VIKING THERAPEUTICS
    • 13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
  • TABLE 2 GLP-1 ANALOGUES MARKET: IMPACT ANALYSIS
  • TABLE 3 AVERAGE SELLING PRICE RANGE OF TOP GLP-1 ANALOGUES (2023–2024)
  • TABLE 4 GLP-1 ANALOGUES IN CLINICAL PIPELINE (AS OF MAY 2024)
  • TABLE 5 TOP 20 PATENT OWNERS IN GLP-1 ANALOGUES MARKET, 2014–2024
  • TABLE 6 INDICATIVE LIST OF PATENTS IN GLP-1 ANALOGUES MARKET, 2022–2024
  • TABLE 7 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
  • TABLE 8 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
  • TABLE 9 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
  • TABLE 10 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
  • TABLE 11 GLP-1 ANALOGUES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 12 BUYING CRITERIA FOR GLP-1 ANALOGUES, BY END USER
  • TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 GLP-1 ANALOGUES MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2024–2025
  • TABLE 18 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 19 GLP-1 ANALOGUES MARKET FOR ANTI-OBESITY PRODUCTS (MILLION UNITS)
  • TABLE 20 OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 21 NORTH AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 22 EUROPE: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 23 ASIA PACIFIC: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 24 LATIN AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 25 MIDDLE EAST: OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 26 GCC COUNTRIES: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 27 TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 28 NORTH AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 29 EUROPE: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 30 ASIA PACIFIC: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 31 LATIN AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 32 MIDDLE EAST: TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 33 GCC COUNTRIES: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 34 MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 35 NORTH AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 36 EUROPE: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 37 ASIA PACIFIC: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 38 LATIN AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 39 MIDDLE EAST: MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 40 GCC COUNTRIES: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 41 WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 42 NORTH AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 43 EUROPE: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 44 ASIA PACIFIC: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 45 LATIN AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 46 MIDDLE EAST: WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 47 GCC COUNTRIES: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 48 RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 49 NORTH AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 50 EUROPE: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 51 ASIA PACIFIC: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 52 LATIN AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 53 MIDDLE EAST: RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 54 GCC COUNTRIES: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 55 SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 56 NORTH AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 57 EUROPE: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 58 ASIA PACIFIC: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 59 LATIN AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 60 MIDDLE EAST: SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 61 GCC COUNTRIES: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 62 VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 63 NORTH AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 64 EUROPE: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 65 ASIA PACIFIC: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 66 LATIN AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 67 MIDDLE EAST: VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 68 GCC COUNTRIES: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 69 XULTOPHY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 70 SOLIQUA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 71 ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 72 NORTH AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 73 EUROPE: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 74 ASIA PACIFIC: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 75 LATIN AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 76 MIDDLE EAST: ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 77 GCC COUNTRIES: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 78 BYDUREON MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 79 OTHER PRODUCTS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 80 GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 81 SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 82 NORTH AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 83 EUROPE: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 84 ASIA PACIFIC: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 85 LATIN AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 86 MIDDLE EAST: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 87 GCC COUNTRIES: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 88 MULTI-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 89 NORTH AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 90 EUROPE: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 91 ASIA PACIFIC: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 92 LATIN AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 93 MIDDLE EAST: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 94 GCC COUNTRIES: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 95 GLP-1 ANALOGUE TABLETS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 96 NORTH AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 97 EUROPE: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 98 ASIA PACIFIC: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 99 LATIN AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 100 MIDDLE EAST: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 101 GCC COUNTRIES: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 102 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 103 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 104 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 105 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 106 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 107 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 108 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 109 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 110 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 111 GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 112 NORTH AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 113 EUROPE: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 114 ASIA PACIFIC: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 115 LATIN AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 116 MIDDLE EAST: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 117 GCC COUNTRIES: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 118 GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 119 NORTH AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 120 EUROPE: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 121 ASIA PACIFIC: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 122 LATIN AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 123 MIDDLE EAST: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 124 GCC COUNTRIES: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 125 ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 126 NORTH AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 127 EUROPE: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 128 ASIA PACIFIC: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 129 LATIN AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 130 MIDDLE EAST: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 131 GCC COUNTRIES: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 132 GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 133 GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 134 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 135 EUROPE: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 136 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 137 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 138 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 139 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 140 GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 141 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 142 EUROPE: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 143 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 144 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 145 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 146 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 147 GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 148 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 149 EUROPE: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 150 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 151 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 152 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 153 GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 154 GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 155 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 156 EUROPE: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 157 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 158 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 159 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 160 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 161 GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 162 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 163 EUROPE: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 164 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 165 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 166 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 167 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 168 GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 169 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 170 EUROPE: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 171 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 172 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 173 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 174 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 175 GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 176 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 177 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 178 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 179 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 180 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 181 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 182 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 183 US: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 184 US: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 185 US: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 186 US: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 187 US: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 188 US: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 189 CANADA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 190 CANADA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 191 CANADA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 192 CANADA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 193 CANADA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 194 CANADA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 195 EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 196 EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 197 EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 198 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 199 EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 200 EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 201 EUROPE: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 202 GERMANY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 203 GERMANY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 204 GERMANY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 205 GERMANY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 206 GERMANY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 207 GERMANY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 208 UK: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 209 UK: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 210 UK: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 211 UK: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 212 UK: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 213 UK: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 214 FRANCE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 215 FRANCE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 216 FRANCE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 217 FRANCE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 218 FRANCE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 219 FRANCE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 220 ITALY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 221 ITALY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 222 ITALY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 223 ITALY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 224 ITALY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 225 ITALY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 226 SPAIN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 227 SPAIN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 228 SPAIN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 229 SPAIN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 230 SPAIN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 231 SPAIN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 232 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 233 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 234 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 235 NETHERLANDS: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 236 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 237 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 238 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 239 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 240 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 241 REST OF EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 242 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 243 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 244 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 245 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 246 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 247 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 248 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 249 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 250 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 251 CHINA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 252 CHINA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 253 CHINA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 254 CHINA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 255 CHINA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 256 CHINA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 257 JAPAN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 258 JAPAN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 259 JAPAN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 260 JAPAN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 261 JAPAN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 262 JAPAN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 263 INDIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 264 INDIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 265 INDIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 266 INDIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 267 INDIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 268 INDIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 269 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 270 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 271 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 272 AUSTRALIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 273 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 274 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 275 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 276 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 277 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 278 SOUTH KOREA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 279 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 280 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 281 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 282 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 283 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 284 REST OF ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 285 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 286 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 287 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 288 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 289 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 290 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 291 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 292 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 293 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 294 BRAZIL: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 295 BRAZIL: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 296 BRAZIL: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 297 BRAZIL: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 298 BRAZIL: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 299 BRAZIL: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 300 MEXICO: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 301 MEXICO: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 302 MEXICO: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 303 MEXICO: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 304 MEXICO: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 305 MEXICO: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 306 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 307 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 308 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 309 REST OF LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 310 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 311 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 312 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 313 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 314 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 315 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 316 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 317 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 318 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 319 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 320 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 321 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 322 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 323 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 324 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 325 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 326 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 327 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 328 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 329 SAUDI ARABIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 330 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 331 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 332 UAE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 333 UAE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 334 UAE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 335 UAE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 336 UAE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 337 UAE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 338 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 339 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 340 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 341 REST OF GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 342 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 343 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 344 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 345 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 346 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 347 REST OF MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 348 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 349 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 350 AFRICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 351 AFRICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 352 AFRICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 353 AFRICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 354 AFRICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 355 AFRICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 356 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 357 GLP-1 ANALOGUES MARKET: DEGREE OF COMPETITION
  • TABLE 358 GLP-1 ANALOGUES MARKET: FORMAT FOOTPRINT
  • TABLE 359 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 360 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
  • TABLE 361 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (KEY PLAYERS)
  • TABLE 362 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
  • TABLE 363 GLP-1 ANALOGUES MARKET: REGION FOOTPRINT (KEY PLAYERS)
  • TABLE 364 GLP-1 ANALOGUES MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 365 GLP-1 ANALOGUES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 366 GLP-1 ANALOGUES MARKET: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 367 GLP-1 ANALOGUES MARKET: DEALS, JANUARY 2021–MAY 2024
  • TABLE 368 GLP-1 ANALOGUES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024
  • TABLE 369 GLP-1 ANALOGUES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
  • TABLE 370 NOVO NORDISK A/S: COMPANY OVERVIEW
  • TABLE 371 NOVO NORDISK A/S: PRODUCTS OFFERED
  • TABLE 372 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
  • TABLE 373 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021–APRIL 2024
  • TABLE 374 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 375 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 376 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 377 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
  • TABLE 378 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 379 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021–APRIL 2024
  • TABLE 380 SANOFI: COMPANY OVERVIEW
  • TABLE 381 SANOFI: PRODUCTS OFFERED
  • TABLE 382 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 383 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 384 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
  • TABLE 385 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
  • TABLE 386 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
  • TABLE 387 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 388 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS IN PIPELINE
  • TABLE 389 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 390 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 391 INNOVENT: COMPANY OVERVIEW
  • TABLE 392 INNOVENT: PRODUCTS IN PIPELINE
  • TABLE 393 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 394 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: COMPANY OVERVIEW
  • TABLE 395 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: PRODUCTS IN PIPELINE
  • TABLE 396 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW
  • TABLE 397 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS IN PIPELINE
  • TABLE 398 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 399 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 400 ZEALAND PHARMA A/S: COMPANY OVERVIEW
  • TABLE 401 ZEALAND PHARMA A/S: PRODUCTS IN PIPELINE
  • TABLE 402 ZEALAND PHARMA A/S: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 403 ZEALAND PHARMA A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 404 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: COMPANY OVERVIEW
  • TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE
  • TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE

List of Figures

  • FIGURE 1 GLP-1 ANALOGUES MARKET SEGMENTATION
  • FIGURE 2 GLP-1 ANALOGUES MARKET: REGIONAL SEGMENTATION
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
  • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
  • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 8 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 9 CAGR PROJECTIONS: GLP-1 ANALOGUES MARKET, 2024–2032
  • FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 ANALOGUES MARKET
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2024 VS. 2032 (USD BILLION)
  • FIGURE 13 GLP-1 ANALOGUES MARKET SHARE, BY FORMAT, 2024 VS. 2032 (USD BILLION)
  • FIGURE 14 GLP-1 ANALOGUES MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD BILLION)
  • FIGURE 15 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2024 VS. 2032 (USD BILLION)
  • FIGURE 16 GLP-1 ANALOGUES MARKET, BY END USER, 2024-2032 (USD BILLION)
  • FIGURE 17 GLP-1 ANALOGUES MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 18 IMPROVED EFFICACY OF GLP-1 DRUGS TO DRIVE MARKET GROWTH
  • FIGURE 19 DIABETES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 20 OZEMPIC TO DOMINATE MARKET IN 2032
  • FIGURE 21 DIABETES INDICATIONS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 22 HOME CARE SETTINGS TO DOMINATE THE MARKET IN 2032
  • FIGURE 23 US TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 24 GLP-1 ANALOGUES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 US: PREVALENCE OF INDICATIONS THAT MAY RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)
  • FIGURE 26 REVENUE SHIFT IN GLP-1 ANALOGUES MARKET
  • FIGURE 27 AVERAGE SELLING PRICE TREND, BY PRODUCT
  • FIGURE 28 PRODUCT PRICING, BY COUNTRY (2023–2024)
  • FIGURE 29 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2025–2032
  • FIGURE 30 PHASE 3 PIPELINE, BY INDICATION
  • FIGURE 31 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
  • FIGURE 32 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
  • FIGURE 33 VALUE CHAIN ANALYSIS: PRODUCT DEVELOPMENT AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
  • FIGURE 34 GLP-1 ANALOGUES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 35 GLP-1 ANALOGUES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 36 GLP-1 ANALOGUES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 ANALOGUES, HOSPITALS
  • FIGURE 38 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 39 NORTH AMERICA GLP-1 ANALOGUES MARKET SNAPSHOT
  • FIGURE 40 EUROPE: GLP-1 ANALOGUES MARKET SNAPSHOT
  • FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2021–2023
  • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2023
  • FIGURE 43 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 44 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
  • FIGURE 45 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
  • FIGURE 46 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
  • FIGURE 47 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 48 EV/EBITDA OF KEY VENDORS
  • FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 50 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTIDIABETIC GLP-1 ANALOGUES)
  • FIGURE 51 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTI-OBESITY GLP-1 ANALOGUES)
  • FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT
  • FIGURE 53 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 54 SANOFI: COMPANY SNAPSHOT
  • FIGURE 55 ASTRAZENECA: COMPANY SNAPSHOT
  • FIGURE 56 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY SNAPSHOT
  • FIGURE 57 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • FIGURE 58 INNOVENT: COMPANY SNAPSHOT
  • FIGURE 59 ZEALAND PHARMA A/S: COMPANY SNAPSHOT